News & Info


Page 3 of 2812345...1020...Last »

July 19, 2016

Anti-depressant Drugs May Someday Help Prevent Macular Degeneration

Posted in: Latest News, Research and Developments

Tests in a mouse model of macular degeneration have shown that anti-depressant drugs already on the market prevent damage to the light cells in the retina. In a study published in Proceedings of the National Academy of Sciences, a University of Wisconsin—Madison research team pinpoints how immune abnormalities beneath the retina result in macular degeneration.
read more »

June 9, 2016

For Some, Switching ANTI-VEGF Treatments Midstream Could Be Harmful

Posted in: Latest News, Research and Developments, Therapies, Treatments, and Procedures

Switching from Lucentis to Eylea could result in worsening of the retinal condition of some people with wet (exudative) AMD. Since the advent of anti-VEGF drug treatments for wet AMD, research has verified that blood vessel growth and leakage (neovascularization) usually diminishes in patients who are switched from either Lucentis or Avastin to Eylea. A small
read more »

May 28, 2016

Summary of Research and Development — 2016

Posted in: Research and Developments

ILVSG Presentation June 2016 Dan Roberts I. INTRODUCTION This is my 11th annual summary of leading research and developments that have occurred during the past 12 months in the field of blindness and low vision. I’ll take the liberty in several cases of quoting the sources, but for the sake of conversational flow, I’ll break
read more »

May 27, 2016

Invitation to participate in paid phone survey

Posted in: Latest News

Cello Health Insight, a Healthcare Market Research Agency, is looking for people with a diagnosis of dry age-related macular degeneration with visual symptoms to participate in a marketing research study. Researchers want to learn about patients’ experiences living with age-related macular degeneration. The study consists of a telephone interview and potentially an in-person interview. This study will
read more »

May 20, 2016

Visual Impairment and Blindness in U.S. May Double by 2050

Posted in: Latest News, Research and Developments

The findings of a recent study suggest that there is a need for increased screening and interventions to identify and address treatable causes of vision loss. With the youngest of the baby boomers hitting 65 by 2029, the number of people with visual impairment or blindness in the United States is expected to double to
read more »

May 5, 2016

OPT-302 Enters Phase 2A Trials for Wet AMD

Posted in: Latest News, Research and Developments

Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has randomized and dosed the first patient in the Phase 2A dose expansion clinical trial of OPT-302 for wet AMD. OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule, that blocks the activity of two
read more »

May 3, 2016

AMD Since Anti-VEGF

Posted in: Latest News, Therapies, Treatments, and Procedures

A National Eye Institute (NEI) study* confirms that anti-VEGF treatments have greatly improved the prognosis for patients with the wet form of age-related macular degeneration (wAMD) during the past decade. In the study of nearly 650 people, half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with
read more »

April 18, 2016

Eye Drops for Wet AMD Enter Phase 3 Trials

Posted in: Latest News

Ohr Pharmaceutical has announced that the first patient has been enrolled in a Phase III clinical trial of the company’s lead drug candidate “Squalamine”, also known as OHR-102, for the treatment of neovascular age-related macular degeneration (wet AMD). “The Phase III clinical program will examine the potential of Squalamine, when administered as part of a combination therapy,
read more »

April 14, 2016

Smoking and AMD—Are E-Cigarettes the Answer?

Posted in: Health and Nutrition, Latest News, Research and Developments

by Dan Roberts You’ve heard it before: “Tobacco Smoking Is A Major Cause Of Age Related Macular Degeneration”. According to most research, individuals 65 years of age and over double their risk of developing age-related macular degeneration (AMD) if they smoke. Why? Because tobacco smoking: Reduces levels of plasma antioxidant, a substance in the blood
read more »

March 23, 2016

Hidden Disabilities: A Social Dilemma

Posted in: Daily Living

by Dan Roberts Margaret’s Story I was making my way down the sidewalk. I heard the clack-clack of skateboard wheels coming at me head-on. I couldn’t see which way to step, so I just froze in place, hoping the child would have good maneuvering skills. He didn’t. He collided with my bad hip, and his
read more »

March 22, 2016

Patient Access Network Foundation and Prevent Blindness Announce New Alliance to Provide Support for People Living With Eye Health Concerns

Posted in: Latest News

The Patient Access Network (PAN) Foundation and Prevent Blindness today announced that they are launching a new alliance to offer holistic support for people living with retinal vein occlusion, macular disease and uveitis. The alliance will enable the organizations to leverage the PAN Foundation’s eye health financial assistance programs and patient resources of Prevent Blindness
read more »

March 11, 2016

Sleeping Too Much Will *Not* Cause Blindness

Posted in: Latest News

Editorial by Dan Roberts Recent research has found an association between longer sleep duration and advanced dry age-related macular degeneration (dAMD), also known as geographic atrophy. This has been misconstrued by at least one media outlet to mean that too much sleep might actually cause the disease. That is absolutely untrue. According to the researchers, “Sleeping
read more »

March 6, 2016

Experimental Gene Therapies Still Raising Hopes

Posted in: Latest News, Research and Developments

Wills Eye Hospital has announced that it has treated the first RESCUE trial patient in the United States enrolled in an FDA-approved gene therapy vision research study. A product called GS010 (GenSight Biologics), can be injected right into the eye and, in a sense, “re-wire” or lower the patient’s risk for getting the disease. The patient has
read more »

March 1, 2016

Similarity of Anti-VEGF Drugs Confirmed For DME Treatment

Posted in: Latest News

A rigorous clinical trial has found that individuals with diabetic macular edema (DME), whose visual acuity is 20/50 or worse, gained more improvement with Eylea than with Avastin. Aside from that, no significant difference was found among the three anti-VEGF drugs (including Lucentis) in subjects with 20/32 or 20/40 vision at the start of treatment. By two years, 41 percent of participants in the
read more »

February 28, 2016

National Eye Institute Receives Funding Increase

Posted in: Latest News

Representatives from Prevent Blindness travel annually to Washington D.C. to advocate for Congressional support of programs and research for the visually impaired. The time spent on Capitol Hill has paid off this year with passage of the Consolidated Appropriations Act of 2016, signed by President Obama in December. Funding has taken some hard hits over
read more »

Page 3 of 2812345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann